Incyte Corporation (INCY) Stock Price Today
Aura AI Summary
Key Stats
- $26.11BMarket Cap
- -Volume
- HealthSector
- $129.9352W High
- $81.6652W Low
- -Typical Hold Time
- $21.62BEnterprise Value
- -Div Yield
- -Trading Activity
Track Incyte Corporation (INCY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Incyte Corporation has traded between a low of $81.66 and a high of $129.93, highlighting its annual price range. Buy and sell Incyte Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Most Recent News
Walmart expands restaurant delivery by adding Dunkin’ to its service via Walmart app.
Walmart is expanding its restaurant delivery service by partnering with Inspire Brands to include Dunkin’ locations, starting with 150 stores inside Walmart before rolling out nationwide. Customers can now order Dunkin’ food and beverages through the...
Central banks increased gold reserves in July, led by China and Poland, with net buying totaling 23 tonnes.
In July, central banks globally increased their gold reserves by a net 23 tonnes, with China and Poland leading the purchases at 20 and 8 tonnes respectively. Emerging markets continue to accumulate gold, with notable buying from the Czech National B...
Gold set for major gains as Fed's rate hikes unlikely to curb inflation or US debt growth.
Gold investors face volatility amid inflation and rate hike concerns, but Eric Strand of AuAg Funds argues the market focuses on the wrong issue. He says inflation is driven by rising commodity costs, not consumer demand, making rate hikes ineffectiv...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.